http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114195741-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8679b30b365eaba9e965a281ab6f9f56
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D301-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D303-36
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D303-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D301-03
filingDate 2021-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_faebd98b6f2ee5d98a85a2978fb47618
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c7045c1cf8503711833421cd8ee572f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce34a330f160f165952729fc187cdde8
publicationDate 2022-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-114195741-A
titleOfInvention Preparation method of carfilzomib key intermediate isomer
abstract The invention provides a preparation method of a carfilzomib key intermediate isomer, which is characterized by comprising the following steps: (1) BOC-D-leucine (SM) is activated by pivaloyl chloride and condensed with morpholine under the action of N-methylmorpholine to obtain a compound 1; (2) reacting the compound 1 with a Grignard reagent under the action of isopropyl magnesium chloride to obtain a compound 2; (3) and oxidizing the compound 2 with sodium hypochlorite to obtain a compound 3 and a compound 4. The method can obtain isomers with high purity, and the purity can meet the requirements of structure identification, impurity spectrum research and methodology verification. Has important significance for the quality research and the quality control of the carfilzomib key intermediate compound 6 and the finished carfilzomib.
priorityDate 2021-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11202
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410510994
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419558781
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450418934
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559283
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449806164
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID637604
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID387447
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID408978442
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6101675
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62493
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416047057
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7972
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3283
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419558806
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419478079
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412183684
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559059
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419497453
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5462224
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11556711
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21226428
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13387
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559552
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8083
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23665760
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8028
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559261
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452802464
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3587356

Total number of triples: 46.